Next Generation Sequencing Testing (NGS)
Estimated value
—
Awarded value
£407k
Suppliers
1
Lots
1
Published
25 Jun 2026
Description
NHS Blood and Transplant (NHSBT) are seeking a provider for Next Generation Sequencing (NGS) QC testing requirements for the Cellular and Molecular Therapies (CMT) directorate, namely the Clinical Biotechnology Centre (CBC). CBC handle a number of products in the production of Advanced Therapeutic Investigational Medicinal Products (ATMPs) and starter material master cell banks (MCBs). These require NGS QC testing services that meet specific regulatory requirements.
Scope
- Reference
- C362396
- Commercial tool
- Standalone contract
- Contract dates
- 31 Mar 2026 to 31 Mar 2027Possible extension to 31 Mar 2028
One (1) year optional extension
- CPV classifications
- 72225000
- Contract locations
- Bristol, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Quality | — | quality | 30.00% |
| Social Value | — | quality | 10.00% |
| Price | — | price | 60.00% |
Participation
Conditions suppliers must meet to bid.
As detailed in tender documents ( https://atamis-1928.my.site.com/ - C362396
As detailed in tender documents ( https://atamis-1928.my.site.com/ - C362396. Must be EU Good Manufacturing Practice (GMP) Licenced.
Submission & procedure
- Procedure
- Competitive flexible procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£407k
Award date
23 Jun 2026
Contract start
31 Jul 2026
Contract end
31 Jul 2027